Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle ( VLP) pandemic influenza vaccine study….
The rest is here:
NOVAVAX Completes Enrollment Of Pivotal H1N1 Influenza Vaccine Clinical Trial In Mexico
Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects. In this Stage B of Novavax’s pivotal study of …
Novavax, Inc. (Nasdaq: NVAX) announced that the enrollment of over 3500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus -like-particle (VLP) pandemic influenza vaccine study. With the 1000 subjects already …
Link:
NOVAVAX Completes Enrollment Of Pivotal H1N1 Influenza Vaccine …
Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
Read the original:
NOVAVAX Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (PharmaceuticalOnline)
ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
Read the original:
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy … (redOrbit)
… Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus -like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. …
View post:
Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine …
Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico.
See the original post here:
NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Influenza Vaccine Study In The Country Of Mexico (Medical News Today)
Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico.
Go here to read the rest:
NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Influenza Vaccine Study In The Country Of Mexico (PharmaceuticalOnline)
Rockville, MD/PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus -like-particle (VLP) pandemic influenza …
Read the original post:
NOVAVAX Completes First Stage Of Enrollment In Pivotal H1N1 Infl